Clotrimaderm: Formulary list price $0.2233/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2233 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11893 · Verify on the e-Formulary ↗ (DIN 00812382)
Source record
DIN 00812382: Clotrimaderm
Raw flags: sec3=Y
Item: 840408012; group id 818; item number 1997; lccId None; manufacturer id TAR
Source form: Cr; strength: 10mg/g
Recorded listing: General benefit
Source prices (unrounded): $0.2233; ministry $0.2233
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00812382
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11893Interchangeable products
Canesten 1% Topical Cream · DIN 02150867 · not recorded
Shortage status: discontinued (2026-02-20, reported by TARO PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00812382
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19483 · Verify on the e-Formulary ↗ (DIN 02150891)
Source record
DIN 02150891: Canesten 6 Cream
Raw flags: sec3=Y
Item: 840408017; group id 818; item number 1999; lccId None; manufacturer id BAY
Source form: Vag Cr-App; strength: 10mg/g
Recorded listing: General benefit
Source prices (unrounded): $0.2212; ministry $0.1812
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02150891
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19483Interchangeable products
Clotrimaderm Vaginal Cream · DIN 00812366 · $0.1812
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02150891
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clotrimaderm Vaginal Cream: Formulary list price $0.1812/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1812 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9926 · Verify on the e-Formulary ↗ (DIN 00812366)
Source record
DIN 00812366: Clotrimaderm Vaginal Cream
Raw flags: sec3=Y
Item: 840408017; group id 818; item number 1999; lccId None; manufacturer id TAR
Source form: Vag Cr-App; strength: 10mg/g
Recorded listing: General benefit
Source prices (unrounded): $0.1812; ministry $0.1812
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00812366
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9926Interchangeable products
Canesten 6 Cream · DIN 02150891 · $0.1812
Shortage status: active shortage (reported 2026-06-17, estimated to end 2026-11-27, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00812366
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19484 · Verify on the e-Formulary ↗ (DIN 02150905)
Source record
DIN 02150905: Canesten 3 Cream
Raw flags: sec3=Y
Item: 840408027; group id 818; item number 2000; lccId None; manufacturer id BAY
Source form: Vag Cr-App; strength: 20mg/g
Recorded listing: General benefit
Source prices (unrounded): $0.4424; ministry $0.3624
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02150905
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19484Interchangeable products
Clotrimaderm Vaginal Cream · DIN 00812374 · $0.3624
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02150905
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clotrimaderm Vaginal Cream: Formulary list price $0.3624/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3624 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9927 · Verify on the e-Formulary ↗ (DIN 00812374)
Source record
DIN 00812374: Clotrimaderm Vaginal Cream
Raw flags: sec3=Y
Item: 840408027; group id 818; item number 2000; lccId None; manufacturer id TAR
Source form: Vag Cr-App; strength: 20mg/g
Recorded listing: General benefit
Source prices (unrounded): $0.3624; ministry $0.3624
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00812374
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9927Interchangeable products
Canesten 3 Cream · DIN 02150905 · $0.3624
Shortage status: resolved shortage (ended 2025-10-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00812374
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Canesten 1 Comfortab Combi-Pak: Formulary list price $12.0800/unit (unit not stated in source; not the patient's cost)
Ministry pays: $12.0800 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74952 · Verify on the e-Formulary ↗ (DIN 02264102)
Source record
DIN 02264102: Canesten 1 Comfortab Combi-Pak
Raw flags: sec3=Y
Item: 840408035; group id 818; item number 1998; lccId None; manufacturer id BAY
Source form: Tab & Cr; strength: 500mg & 1%
Recorded listing: General benefit
Source prices (unrounded): $12.0800; ministry $12.0800
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02264102
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74952
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02264102
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Canesten 1% Topical Cream: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19487 · Verify on the e-Formulary ↗ (DIN 02150867)
Source record
DIN 02150867: Canesten 1% Topical Cream
Raw flags: notABenefit=Y, sec3=Y
Item: 840408012; group id 818; item number 1997; lccId None; manufacturer id BAY
Source form: Cr; strength: 10mg/g
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02150867
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19487Interchangeable products
Clotrimaderm · DIN 00812382 · $0.2233
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02150867
Shortage record checked 2026-09-13T08:10:21.292534+00:00
CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (D01A, D01AC, G01A) — coverage varies; not interchangeable
Ketoconazole (Nizoral): general benefit, Not a benefit
Miconazole nitrate (Micatin): general benefit
Nystatin (Mycostatin): general benefit, Not a benefit
Terbinafine (Lamisil): general benefit
Terconazole (Terazol 7): general benefit, Not a benefit
Ciclopirox (Penlac): not a benefit
Lotriderm Cream · DIN 00611174 · 1% w/w & 0.05% w/w · Top Cr
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists LOTRIDERM CREAM (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lotriderm Cream · DIN 00611174
Manufacturer: Merck Canada Inc.; listing date 2020-06-30
Health Canada: Marketed since 2022-03-10 · brand LOTRIDERM · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS, D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %, CLOTRIMAZOLE 1 % · company Organon canada inc. · schedule Prescription
Lotriderm Cream: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10748 · Verify on the e-Formulary ↗ (DIN 00611174)
Source record
DIN 00611174: Lotriderm Cream
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id MEK
Source form: Top Cr; strength: 1% w/w & 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00611174
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10748Interchangeable products
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · not recorded
Shortage status: resolved shortage (ended 2020-04-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00611174
Shortage record checked 2026-09-13T08:10:21.292534+00:00
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · 1% w/w & 0.05% w/w · Top Cr
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-06-30
Health Canada: Marketed since 2020-04-06 · brand TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS, D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients CLOTRIMAZOLE 1 %/W/W, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629 · Verify on the e-Formulary ↗ (DIN 02496410)
Source record
DIN 02496410: TaroClotrimazole/BetamethasoneDipropiona
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id TAR
Source form: Top Cr; strength: 1% w/w & 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0832; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496410
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629Interchangeable products
Lotriderm Cream · DIN 00611174 · not recorded
Shortage status: resolved shortage (ended 2026-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496410
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered
Matched class: 84:04:08 Fungicides
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL
Some products covered without a code (check the product listing): KETOCONAZOLE, NYSTATIN, TERCONAZOLE
84:04:08 Fungicides
1 INDICATIONS
Clotrimaderm Vaginal 6 (clotrimazole) is indicated for the 6-day treatment of vaginal candidiasis.
Clotrimaderm Vaginal 3 (clotrimazole) is indicated for the 3-day treatment of vaginal candidiasis.
1.1 Pediatrics
Pediatrics (>12 years of age): Based on the data submitted and reviewed by Health Canada, the safety
and efficacy of Clotrimazole in pediatric patients (>12 years of age) has been established. Therefore,
Health Canada has authorized an indication for pediatric (>12 years of age) use.
https://pdf.hres.ca/dpd_pm/00081078.PDF
PM date: July 16, 2025
Source product: CLOTRIMADERM VAGINAL 6; DIN 00812366; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
LOTRIDERM® Cream (betamethasone dipropionate and clotrimazole) is indicated for:
the topical treatment of the following fungal dermal infections complicated by inflammatory
pruritus: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum,
Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis.
1.1 Pediatrics
Pediatrics: Based on the available data, the safety and effectiveness in children below the age
of 12 have not been established with LOTRIDERM® Cream.
1.2 Geriatrics
Geriatrics: There is insufficient data to suggest that use in the geriatric population is associated
with differences in safety or effectiveness.
https://pdf.hres.ca/dpd_pm/00060782.PDF
PM date: April 20, 2021
Source product: LOTRIDERM; DIN 00611174; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Clotrimaderm · DIN 00812382
Shortage status: discontinued (2026-02-20, reported by TARO PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00812382
Clotrimaderm Vaginal Cream · DIN 00812366
Shortage status: active shortage (reported 2026-06-17, estimated to end 2026-11-27, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00812366
For Canesten 1% Topical Cream, Lotriderm Cream, TaroClotrimazole/BetamethasoneDipropiona: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.